---
document_datetime: 2025-12-02 05:27:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/desloratadine-krka.html
document_name: desloratadine-krka.html
version: success
processing_time: 0.0724898
conversion_datetime: 2025-12-25 05:04:40.421523
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Desloratadine Krka

[RSS](/en/individual-human-medicine.xml/66000)

##### Application withdrawn

The application for this medicine has been withdrawn

desloratadine Medicine Human Application withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Key facts](#key-facts)
- [All documents](#all-documents)
- [Related information on withdrawals](#related-info-withdrawn)
- [More information on Desloratadine Krka](#more-information-on-desloratadine-krka-62327)
- [Related documents](#related-documents-63569)
- [Topics](#topics)

- Application under evaluation
- Withdrawal of application

## Overview

On 14 October 2011, Krka, d.d., Novo mesto officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Desloratadine Krka, for the relief of symptoms of allergic rhinitis or urticaria.

Expand section

Collapse section

## What is Desloratadine Krka?

Desloratadine Krka is a medicine containing the active substance desloratadine. It was to be available as tablets.

Desloratadine Krka was developed as a 'generic medicine'. This means that Desloratadine Krka was intended to be similar to a 'reference medicine' already authorised in the European Union called Aerius. For more information on generic medicines, see the question-and-answer document here.

## What was Desloratadine Krka expected to be used for?

Desloratadine Krka was to be used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).

## How is Desloratadine Krka expected to work?

The active substance in Desloratadine Krka, desloratadine, is an antihistamine. It works by blocking the receptors on which histamine, a substance in the body that causes allergic symptoms, normally fixes itself. When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy.

## What did the company present to support its application?

Because Desloratadine Krka was developed as a generic medicine, the company presented the results of studies carried out to investigate whether it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## How far into the evaluation was the application when it was withdrawn?

The evaluation had finished and the CHMP had given a positive opinion. The company withdrew before the European Commission had issued a decision on this opinion.

## What was the recommendation of the CHMP at that time?

Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had given a positive opinion, recommending that a marketing authorisation be granted for Desloratadine Krka for the relief of symptoms of allergic rhinitis or urticaria.

## What were the reasons given by the company for withdrawing the application?

The letter from the company notifying the Agency of the withdrawal of the application is available under the tab 'All documents'.

Questions and answers on the withdrawal of the marketing authorisation application for Desloratadine Krka

Reference Number: EMA/CHMP/839195/2011

English (EN) (58.21 KB - PDF)

**First published:** 17/11/2011

**Last updated:** 17/11/2011

[View](/en/documents/medicine-qa/questions-and-answers-withdrawal-marketing-authorisation-application-desloratadine-krka_en.pdf)

## Key facts

Name of medicine Desloratadine Krka Active substance desloratadine International non-proprietary name (INN) or common name desloratadine Therapeutic area (MeSH)

- Rhinitis, Allergic, Perennial
- Rhinitis, Allergic, Seasonal

Anatomical therapeutic chemical (ATC) code R06AX27 EMA product number EMEA/H/C/002461

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation applicant Krka, d.d., Novo mesto Withdrawal of application 14/10/2011

## All documents

Withdrawal assessment report for Desloratadine Krka

Adopted

Reference Number: EMA/32973/2012

English (EN) (198.65 KB - PDF)

**First published:** 26/01/2012

**Last updated:** 26/01/2012

[View](/en/documents/withdrawal-report/withdrawal-assessment-report-desloratadine-krka_en.pdf)

Withdrawal letter: Desloratadine Krka

English (EN) (37.86 KB - PDF)

**First published:** 17/11/2011

**Last updated:** 17/11/2011

[View](/en/documents/withdrawal-letter/withdrawal-letter-desloratadine-krka_en.pdf)

#### Related information on withdrawals

A question-and-answer (Q&amp;A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

#### More information on Desloratadine Krka

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related documents

Krka, d.d., Novo mesto withdraws its marketing authorisation application for Desloratadine Krka (desloratadine)

Reference Number: EMA/840073/2011

English (EN) (56.62 KB - PDF)

**First published:** 19/10/2011

**Last updated:** 19/10/2011

[View](/en/documents/press-release/krka-dd-novo-mesto-withdraws-its-marketing-authorisation-application-desloratadine-krka-desloratadine_en.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/11/2011

## Share this page

[Back to top](#main-content)